Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database
Authors' conclusion
Combination therapy with pioglitazone and SGLT2is is an effective treatment in the primary prevention of MACE and heart failure in patients with type 2 diabetes.
Study context
- Population
- T2D patients without a history of CVD, Taiwan National Health Insurance Research Databasepropensity-matched
- Participants
- 15,601 / 15,601 / 15,601 / 15,601
- Exposure
- SGLT2i + pioglitazone, SGLT2i, or pioglitazone vs non-study drugs
- Pioglitazone/SGLT2i combinationn = 15,601
- SGLT2in = 15,601
- Pioglitazonen = 15,601
- Non-study drugsn = 15,601reference
- Outcome
- 3-point major adverse cardiovascular events (MACE):
- MI
- Stroke
- Cardiovascular death
Methodological detailsnationwide database, propensity-score matched
- Nationwide database
- Propensity-score matched
Main finding
As reported in the abstract
3-point MACE
Each group vs non-study drugsAdjusted hazard ratio (95 % CI)
Pioglitazone/SGLT2i combination
0.76(0.66–0.88)
Pioglitazone
0.82(0.71–0.94)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | aHR (95 % CI) | |
|---|---|---|
| Incident HFPioglitazone/SGLT2i combinationvs Non-study drugs | 0.67 (0.55–0.82) | |
| Incident HFSGLT2ivs Non-study drugs | 0.7 (0.58–0.86) | |
| 0.512Adjusted hazard ratio (log scale) |
Incident HF
- Pioglitazone: no difference in risk of HF vs reference
Original publication
Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database. Diabetes Res Clin Pract. Published 24 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →